We use cookies for a better user experience. Read our Privacy Policy

I Agree

Global Human Reproductive Technologies Market to Reach Valuation of US$27.1 bn by 2019 due to Growing Demand for Contraceptives

Pharmaceutical |

A recent report on the global human reproductive technologies market has been published by Transparency Market Research. The report, titled “Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019,” projects this market to expand at a CAGR of 2.20% during the period from 2013 to 2019. The market is estimated to stand at a valuation of US$27.1 bn by 2019.According to the World Health Organization, in 2010, about 1.9% of the female population worldwide in the age group of 20-44 years was unable to conceive the first child. The growing prevalence of infertility has been attributed to a number of environmental and socio-economic factors. The various human reproductive technologies have witnessed increasing popularity in the past couple of years for the treatment of infertility among both men and women.

Browse the full Human Reproductive Technologies Market (Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019 report at https://www.transparencymarketresearch.com/human-reproductive-technologies-market.html

With the rise in female employment, there has been a growing trend of a delay in conception. Factors such as pollution, smoking, stress, and obesity have led to an increase in infertile population. The growing prevalence of unwanted pregnancies, initiatives taken by governments and NGOs to promote contraceptive products, and the implementation of favorable policies such as the Affordable Care Act has propelled the growth of the global human reproductive technologies market.

However, limited insurance coverage and the side effects of contraceptive drugs and devices might hamper the growth of the market during the forecast period. The global human reproductive technologies market has a significant opportunity to grow with the rise in medical tourism, government support for the treatment of infertility, and the presence of a strong pipeline of contraceptive drugs.

The market for contraceptives stood at a valuation of US$16 bn in 2012. During the forecast period, the market is estimated to expand at a CAGR of 5.5%. In 2012, the oral contraceptives segment witnessed the highest demand due to the availability of contraceptives as an over-the-counter drug.

The key regions in the global human reproductive technologies market are Europe, Asia Pacific, North America, and Rest of the World. In 2012, North America emerged as the leading region in the market, followed by Europe. North America is predicted to dominate the market throughout the forecast period. However, the market is projected to register the fastest growth in Asia Pacific due to the increasing awareness about contraceptives, high population density, and rise in disposable income.

Some of the major players in the global human reproductive technologies market are Bayer AG, Abbott Laboratories, Actavis Inc., Boston Scientific Corporation, Church & Dwight Co. Inc., Merck KGaA, Warner Chilcott plc, Reckitt Benckiser Group plc, Merck Serono, Pfizer Inc., Johnson & Johnson, Cook Medical Inc., and Teva Pharmaceutical Industries Ltd. The report discusses some of the key attributes of the market players including their business strategies, product portfolio, and recent developments. Through a SWOT analysis, the report identifies the future growth opportunities for the market vendors.

Global human reproductive technologies market has been segmented as:

Human Reproductive Technologies Market by Infertility Drugs

  • Gonal-f (recombinant follitropin alfa)
  • Follistim AQ (follitropin beta)
  • AndroGel (testosterone)
  • Testim (testosterone)
  • Viagra (sildenafil citrate)
  • Cialis (tadalafil)
  • Levitra/Staxyn (vardenafil)

Human Reproductive Technologies Market, by Infertility Procedures

  • In Vitro Fertilization (IVF)
  • Intracytoplasmic Sperm Injection (ICSI)
  • Zygote Intrafallopian Transfer (ZIFT)
  • Gamete Intrafallopian Transfer (GIFT)
  • Intrauterine Insemination (IUI)

Human Reproductive Technologies Market, by Contraceptive Technologies


  • Oral Contraceptive Pills
  • Contraceptive Injectables
  • Topical Contraceptives


  • Male Contraceptive Devices (Male Condoms)
  • Female Contraceptive Devices

Major geographies analyzed under this research report are: 

  • Europe
  • North America 
  • Asia-Pacific 
  • Rest of the World 

About Us 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.


Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Copyright © Transparency Market Research, Inc. All Rights reserved